Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-econazole is the S-enantiomer of econazole, an imidazole-class antifungal agent. Econazole acts by inhibiting fungal cytochrome P450 enzyme 14α-demethylase, which is essential for converting lanosterol to ergosterol—a key component of fungal cell membranes. Inhibition leads to increased membrane permeability and leakage of cellular contents, resulting in fungistatic or fungicidal effects. While racemic econazole is widely used topically for dermatophytoses and cutaneous candidiasis, the specific clinical use or approval status of isolated (S)-econazole as a single enantiomer appears experimental[5]. The compound has also been described as having some activity against Gram-positive bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-econazole.